New Blog Post:
First-in-Human Results for GB-0669: Durable Neutralization from an AI-Designed Antibody
Announcement:
Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma
Contact
Curious about our work? Get in touch.
InvestorsJason Silversinvestors@generatebiomedicines.com
Media InquiriesMegan McLaughlinpr@generatebiomedicines.com
Collaboration& PartnershipsSahm Nasseripartner@generatebiomedicines.com